Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448128 | 0.82 | ADRA2B (0.35) | TSHR | |
| SCHEMBL8105157 | 0.81 | LTA4H (0.38) | LTA4HMEN1KMT2A | |
| SCHEMBL160311 | 0.79 | ALDH1A1 (0.46) | TSHRMEN1KMT2A | |
| SCHEMBL28558829 | 0.77 | ALDH1A1 (0.44) | TSHRMEN1KMT2A | |
| SCHEMBL27755603 | 0.77 | ALDH1A1 (0.44) | TSHRMEN1KMT2A | |
| SCHEMBL28636919 | 0.77 | ALDH1A1 (0.44) | TSHRMEN1KMT2A | |
| SCHEMBL4658283 | 0.76 | CHRNB2 (0.39) | LTA4HTSHR | |
| SCHEMBL28750369 | 0.74 | CHRNB2 (0.38) | LTA4HTSHR | |
| SCHEMBL996139 | 0.73 | HRH3 (0.39) | TSHRMEN1KMT2A | |
| SCHEMBL136235 | 0.72 | GABRA1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PHOSPHOENIX SARL (FR) | 2010-04-22 | — | — | US | claimed |
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PHOSPHOENIX SARL (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099875-A1 | NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS | PNP, NANP, PHOSPHO1 | HDAC1 1804/4885HDAC8 3582/4885HDAC6 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.